Militia Long/Short Equity ETF ORR
38.54 USD -0.09 (-0.23%)
Nov 4, 2026, 11:31 AM EST
38.46 Day range 39.09
31.70 52-week range 39.80
- YTD
- +12.82%
- 1 year
- +21.19%
- Market cap
- 37.60M
- EPS (ttm)
- 2.99
- P/E ratio
- 12.90
- YTD return
- +12.82%
- 1-year return
- +21.19%
- Volume
- 156.20K
- Avg volume
- 53.39K
- Open
- 38.98
- Previous close
- 38.63
- Day's range
- 38.46 – 39.09
- 52-week range
- 31.70 – 39.80
6M +2.78 (+7.75%)
News
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S 
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer 
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer 
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer 
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER 
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026 
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer 
/C O R R E C T I O N - AbbVie/
Your note
Sign in to keep a note on ORR — it syncs with the Stock Master app.